We read with interest the Article by Peter G Gibson and colleagues (July 4, 2017, p 659),¹ which clearly showed the beneficial effects of macrolide therapy on the incidence of asthma exacerbations. Increasingly, asthma is recognised as a heterogeneous disease with multiple phenotypes and endotypes. By contrast with the effects of anti-inflammatory treatment with inhaled corticosteroids, leukotriene receptor antagonists, and biological therapies—for which therapeutic efficacy depends on the inflammatory profile—Gibson and colleagues showed no differential benefit in terms of eosinophilic inflammation over non-eosinophilic inflammation.

中文翻译：

---

阿奇霉素如何改善哮喘发作？

我们感兴趣地阅读了Peter G Gibson及其同事的文章（2017年7月4日，第659页），¹清楚地表明了大环内酯疗法对哮喘加重发生率的有益作用。越来越多地，哮喘被认为是具有多种表型和内型的异质性疾病。与吸入皮质类固醇，白三烯受体拮抗剂和生物疗法的抗炎治疗效果相反（这些疗法的疗效取决于炎症状况），吉布森及其同事在嗜酸性粒细胞炎症方面比非嗜酸性粒细胞炎症没有显示出不同的益处。